ELISA Phospho-JUN (Thr93) anti-

Quantity :100µL Clone Number: Aliases:Activator protein 1 antibody; AP 1 antibody; AP-1 antibody; AP1 antibody; cJun antibody; Enhancer Binding Protein AP1 antibody; Jun Activation Domain Binding Protein antibody; JUN antibody; Jun oncogene antibody; JUN protein antibody; Jun proto oncogene antibody; JUN_ antibody; JUNC antibody; Oncogene JUN antibody; p39 antibody; Proto oncogene c jun antibody; Proto oncogene cJun antibody; Proto-oncogene c-jun antibody; Transcription Factor AP 1 antibody; Transcription factor AP-1 antibody; Transcription Factor AP1 antibody; V jun avian sarcoma virus 17 oncogene homolog antibody; V jun sarcoma virus 17 oncogene homolog (avian) antibody; V jun sarcoma virus 17 oncogene homolog antibody; V-jun avian sarcoma virus 17 oncogene homolog antibody; vJun Avian Sarcoma Virus 17 Oncogene Homolog antibody Product Type:Polyclonal Antibody Immunogen Species:Homo sapiens () UniProt ID:P05412 Immunogen:Peptide sequence around phosphorylation site of threonine 93 (T-P-T(p)-P-T) derived from c-Jun. Raised in:Rabbit Reactivity:, Mouse, Rat Tested Applications:ELISA, WB, IHC; WB:1:500-1:1000, IHC:1:50-1:100 Background:Transcription factor that recognizes and binds to the enhancer heptamer motif 5'-TGA[CG]TCA-3'. Binetruy B, et al. (1991) Nature. 351: 122-127. Smeal T, et al. (1991) Nature. 354:494-496. Derijard B, et al. (1994) Cell. 76:1025-1037. Kyriakis J M, et al. (1994) Nature. 369: 156-160. Clonality:Polyclonal Isotype:IgG Purification Method:Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjµgates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatogramphy usi Conjµgate:Non-conjµgated Buffer:Supplied at 1.0mg/mL in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Form:liquid Stroage:Upon receipt, store at -20°C or -80°C. Avoid repeated freeze. Target Names:JUN Research Areas:Epigenetics and Nuclear Signaling;Cancer;Immunology;Signal transduction